

TABLE S7 - IRESSA vs TARCEVA IC50

Cell Line		Subtype	Mutation	IC50s Gefitinib (Iressa)			IC50s Erlotinib (Tarceva)		
				Assays	Average	SD	Assays	Average	SD
A	549	AD	mKRAS	4	25	10	4	60	47
Calu	3	AD	WT	4	0.78	0.36	4	1.29	0.77
H	157	SQ	mKRAS	4	115	18	4	128	19
H	322	AD	WT	6	120	45	5	56	53
H	358	AD	mKRAS	4	12.5	1.8	3	6.2	1.9
H	441	AD	mKRAS	4	15.7	1.9	4	7.1	1.8
H	460	LC	mPIK3CA	4	16.9	2	4	72	26
H	820	AD	mEGFR	6	3	2.2	6	7.1	4.1
H	1155	LCC	mKRAS	3	183	58	2	8.63	
H	1299	LC	WT	8	26.4	4.2	7	41.9	3.3
H	1355	AD	mKRAS	4	325	24	6	27	24
H	1395	AD	mBRAF	3	71	18	4	10.5	5.1
H	1437	AD	WT	3	62	12	4	12.5	7.2
H	1573	AD	WT	4	11.9	3.2	ND		
H	1648	AD	WT	4	36.7	8.5	4	34	30
H	1650	AD	mEGFR	8	11.7	4.6	8	15	3.3
H	1666	BA	mBRAF	4	180	150	6	13	27
H	1770	NE	WT	8	160	210	3	111	18
H	1781	BA	mHER2	6	19	16	6	44	38
H	1819	AD	WT	4	19	2.8	6	6.3	1.2
H	1975	AD	mEGFR	4	25	8.1	4	33	24
H	1993	AD	WT	4	17.9	7.3	4	5.2	2.8
H	2009	AD	mKRAS	6	33.2	8.7	4	25.8	5
H	2073	AD	WT	4	0.0315	0.0012	4	0.0313	0.0009
H	2087	AD	mBRAF	3	18.4	4.9	4	9.9	3.4
H	2122	AD	mKRAS	4	35	16	4	76.8	4
H	2126	LCC	WT	4	21.4	4.1	6	13	11
H	2170	SQ	WT	4	3.2	1.6	ND		
H	2347	AD	WT	4	60	43	4	5.2	3.4
H	2882	NS	WT	4	19.2	7.5	4	66	18
H	2887	AD	mKRAS	4	110	100	4	101	7
H	3255	AD	mEGFR	4	0.089	0.063	3	0.129	0.016
HCC	15	SQ	mHER4	4	52	19	4	100	7
HCC	44	AD	mKRAS	4	57.8	9.4	4	28	5.3
HCC	78	AD	WT	4	81	8.4	3	21.2	5.6
HCC	95	SQ	WT	4	24	17	4	18.4	4.6
HCC	193	AD	WT	4	21.1	9.9	3	20.5	4.8
HCC	366	AD	WT	9	30	31	4	11	2
HCC	461	AD	mKRAS	4	13.9	5.3	4	16	16
HCC	515	AD	mKRAS	7	120	120	4	154	76
HCC	827	AD	mEGFR	16	0.04	0.028	6	0.0388	0.0096
HCC	1171	AD	mKRAS	4	127	26	4	160	48
HCC	1195	MIXED	WT	4	27.6	6.7	3	175	28
HCC	1359	LC	WT	5	65	52	3	88	43
HCC	2279	AD	mEGFR	6	0.0479	0.0066	4	0.093	0.048
HCC	2935	AD	mEGFR	4	0.11	0.056	4	0.163	0.07
HCC	4006	AD	mEGFR	7	0.23	0.19	4	0.124	0.014
HCC	4011	AD	mEGFR	8	0.6		ND		
PC	9	AD	mEGFR	4	0.0309	0.0016	ND		

m-	mutation
ND	not done
AD	Adenocarcinoma
LC	Large Cell Carcinoma
SQ	Squamous Cell Carcinoma
ADSQ	Adenosquamous Carcinoma
NS	Not specific